In this OncLiveTV video, watch Wojciech Jurczak, MD Head of Lymphoma, Department of Hematology from the Jagiellonian University, Poland, talk about MOR208 for non-Hodgkin’s lymphoma treatments.
According to OncLive, MOR208 is “a monoclonal antibody directed against the antigen CD19” and it was “given to patients for at least 3 months.”
“The 30% response rate was more than expected,” Jurczak stated.
Lymphoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.